Fluphenazine Decanoate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 526556

CAS#: 5002-47-1

Description: Fluphenazine Decanoate is an antipsychotic agent, blocking postsynaptic dopamine D2 receptors in the limbic, cortical system and basal ganglia.

Chemical Structure

img
Fluphenazine Decanoate
CAS# 5002-47-1
Instruction

Theoretical Analysis

MedKoo Cat#: 526556
Name: Fluphenazine Decanoate
CAS#: 5002-47-1
Chemical Formula: C32H44F3N3O2S
Exact Mass: 591.31
Molecular Weight: 591.780
Elemental Analysis: C, 64.95; H, 7.49; F, 9.63; N, 7.10; O, 5.41; S, 5.42

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Fluphenazine Decanoate

IUPAC/Chemical Name: 2-[4-[3-[2-(Trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethyl decanoate

InChi Key: VIQCGTZFEYDQMR-UHFFFAOYSA-N

InChi Code: InChI=1S/C32H44F3N3O2S/c1-2-3-4-5-6-7-8-14-31(39)40-24-23-37-21-19-36(20-22-37)17-11-18-38-27-12-9-10-13-29(27)41-30-16-15-26(25-28(30)38)32(33,34)35/h9-10,12-13,15-16,25H,2-8,11,14,17-24H2,1H3

SMILES Code: CCCCCCCCCC(OCCN1CCN(CCCN2C3=C(C=CC=C3)SC4=CC=C(C(F)(F)F)C=C24)CC1)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 591.78 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Siragusa S, Saadabadi A. Fluphenazine. 2017 Oct 10. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2017 Jun-. Available from http://www.ncbi.nlm.nih.gov/books/NBK459194/ PubMed PMID: 29083807.

2: Umino M, Kobayashi R, Nisijima K, Suda S. Late-Onset Rhabdomyolysis Associated With an Intramuscular Injection of Fluphenazine Decanoate. Prim Care Companion CNS Disord. 2017 Sep 28;19(5). pii: 16l02078. doi: 10.4088/PCC.16l02078. PubMed PMID: 28972705.

3: Omi T, Mitsui Y, Matsunaga H. Long-acting formulation leading to severe long-term adverse effects: a case report of fluphenazine and persistent extrapyramidal symptoms. J Clin Pharm Ther. 2017 Jul 17. doi: 10.1111/jcpt.12589. [Epub ahead of print] PubMed PMID: 28718220.

4: Lytle S, McVoy M, Sajatovic M. Long-Acting Injectable Antipsychotics in Children and Adolescents. J Child Adolesc Psychopharmacol. 2017 Feb;27(1):2-9. doi: 10.1089/cap.2016.0055. Epub 2017 Jan 23. PubMed PMID: 28112539.

5: Zhao YJ, Lin L, Teng M, Khoo AL, Soh LB, Furukawa TA, Baldessarini RJ, Lim BP, Sim K. Long-term antipsychotic treatment in schizophrenia: systematic review and network meta-analysis of randomised controlled trials. BJPsych Open. 2016 Feb 5;2(1):59-66. eCollection 2016 Jan. PubMed PMID: 27703755; PubMed Central PMCID: PMC4995551.

6: Wagman JD, Wolfe BA, Schook MW. The effect of fluphenazine decanoate on glucocorticoid production, reproductive cyclicity, and the behavioral stress response in the Persian onager (Equus hemionus onager). Zoo Biol. 2015 Nov;34(6):525-34. doi: 10.1002/zoo.21250. Epub 2015 Oct 22. PubMed PMID: 26491959.

7: Marcus SC, Zummo J, Pettit AR, Stoddard J, Doshi JA. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge. J Manag Care Spec Pharm. 2015 Sep;21(9):754-68. PubMed PMID: 26308223.

8: Chou YH, Chu PC, Wu SW, Lee JC, Lee YH, Sun IW, Chang CL, Huang CL, Liu IC, Tsai CF, Yen YC. A Systemic Review and Experts' Consensus for Long-acting Injectable Antipsychotics in Bipolar Disorder. Clin Psychopharmacol Neurosci. 2015 Aug 31;13(2):121-8. doi: 10.9758/cpn.2015.13.2.121. PubMed PMID: 26243837; PubMed Central PMCID: PMC4540044.

9: Doshi JA, Pettit AR, Stoddard JJ, Zummo J, Marcus SC. Concurrent Oral Antipsychotic Drug Use Among Schizophrenia Patients Initiated on Long-Acting Injectable Antipsychotics Post-Hospital Discharge. J Clin Psychopharmacol. 2015 Aug;35(4):442-6. doi: 10.1097/JCP.0000000000000353. PubMed PMID: 26075492.

10: Maayan N, Quraishi SN, David A, Jayaswal A, Eisenbruch M, Rathbone J, Asher R, Adams CE. Fluphenazine decanoate (depot) and enanthate for schizophrenia. Cochrane Database Syst Rev. 2015 Feb 5;(2):CD000307. doi: 10.1002/14651858.CD000307.pub2. Review. PubMed PMID: 25654768.

11: Nielsen J, Jensen SO, Friis RB, Valentin JB, Correll CU. Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study. Schizophr Bull. 2015 May;41(3):627-36. doi: 10.1093/schbul/sbu128. Epub 2014 Sep 1. PubMed PMID: 25180312; PubMed Central PMCID: PMC4393684.

12: Uchida H, Suzuki T. Dose and dosing frequency of long-acting injectable antipsychotics: a systematic review of PET and SPECT data and clinical implications. J Clin Psychopharmacol. 2014 Dec;34(6):728-35. doi: 10.1097/JCP.0000000000000065. Review. PubMed PMID: 24781442.

13: Weiss RB, Schook MW, Wolfe BA. Long-acting neuroleptic use for reproductive management of non-domestic ungulates using the domestic goat (Capra hircus) as a model. Zoo Biol. 2014 May-Jun;33(3):204-11. doi: 10.1002/zoo.21125. Epub 2014 Mar 18. PubMed PMID: 24644127.

14: Takashi T, Uchida H, Suzuki T, Mimura M. Effectiveness of saikokaryukotsuboreito (herbal medicine) for antipsychotic-induced sexual dysfunction in male patients with schizophrenia: a description of two cases. Case Rep Psychiatry. 2014;2014:784671. doi: 10.1155/2014/784671. Epub 2014 Jan 27. PubMed PMID: 24587934; PubMed Central PMCID: PMC3921956.

15: Nielssen O, Fukui A, Fawkner L, Walker K. Va'a fakalelei 'atamai: restoring the mind in the Kingdom of Tonga. Australas Psychiatry. 2014 Apr;22(2):183-5. doi: 10.1177/1039856214520792. Epub 2014 Feb 10. PubMed PMID: 24516194.

16: Costello S, Heffron B, Taddei L, Benoit M, Hurt L, Simpson L, Bishop J, Folker-Calderon D, Negrusz A. Quantitation of fluphenazine in equine serum following fluphenazine decanoate administration. J Anal Toxicol. 2013 Oct;37(8):594-9. doi: 10.1093/jat/bkt073. Epub 2013 Aug 28. PubMed PMID: 23986099.

17: Uchida T, Suzuki T, Sakurai H, Tsutsumi C, Den R, Mimura M, Uchida H. Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review. Int Clin Psychopharmacol. 2013 Sep;28(5):261-6. doi: 10.1097/YIC.0b013e328363aa5a. PubMed PMID: 23820334.

18: Stanković Z, Ille T. Adherence to depot versus oral antipsychotic medication in schizophrenic patients during the long-term therapy. Vojnosanit Pregl. 2013 Mar;70(3):267-73. PubMed PMID: 23607237.

19: Kirk Morton N, Zubek D. Adherence challenges and long-acting injectable antipsychotic treatment in patients with schizophrenia. J Psychosoc Nurs Ment Health Serv. 2013 Mar;51(3):13-8. PubMed PMID: 23547305.

20: Park EJ, Amatya S, Kim MS, Park JH, Seol E, Lee H, Shin YH, Na DH. Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia. Arch Pharm Res. 2013 Jun;36(6):651-9. doi: 10.1007/s12272-013-0105-7. Epub 2013 Apr 1. Review. PubMed PMID: 23543652.